Posted on February 15, 2019 by Sitemaster
Also on Thursday in San Francisco, Dr. Karim Fizazi presented the initial results from the ARAMIS trial of darolutamide (formerly known as ODM-201) in the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: ARAMIS, castration-resistant, darolutamide, nmCRPC, non-metastatic, ODM-201 | 6 Comments »
Posted on October 25, 2018 by Sitemaster
Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, darolutamide, hormone-sensitive, metastatic, non-metastatic, ODM-201 | 4 Comments »
Posted on August 7, 2017 by Sitemaster
A while back now (in late 2014) Bayer initiated Phase III trials of the investigational agent ODM-201 — now also known as daralutamide — in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration-resistant, daralutamide, metastatic, nmCRPC, non-metatstatic, ODM-201 | Leave a comment »
Posted on September 16, 2014 by Sitemaster
According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen, castration-resistant, CRPC, inhibitor, ODM-201, receptor | 10 Comments »
Posted on July 30, 2014 by Sitemaster
ODM-201 is a new androgen receptor inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, metastatic, non-metastatic, ODM-201 | Leave a comment »
